Business Description
Neumora Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US6409791000
Description
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 86.79 | |||||
| Equity-to-Asset | 0.95 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -83.3 | |||||
| 3-Year EPS without NRI Growth Rate | -77.1 | |||||
| 3-Year FCF Growth Rate | -138.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 14.42 | |||||
| 9-Day RSI | 18.84 | |||||
| 14-Day RSI | 23.71 | |||||
| 6-1 Month Momentum % | 2.6 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 19.05 | |||||
| Quick Ratio | 19.05 | |||||
| Cash Ratio | 18.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.5 | |||||
| Shareholder Yield % | -0.01 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -3026.61 | |||||
| ROA % | -35.41 | |||||
| ROIC % | -459.04 | |||||
| ROC (Joel Greenblatt) % | -1914.7 | |||||
| ROCE % | -39.67 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.1 | |||||
| Price-to-Tangible-Book | 3.1 | |||||
| EV-to-EBIT | -5.8 | |||||
| EV-to-EBITDA | -5.81 | |||||
| EV-to-FCF | -9.98 | |||||
| Price-to-Net-Current-Asset-Value | 3.22 | |||||
| Price-to-Net-Cash | 3.4 | |||||
| Earnings Yield (Greenblatt) % | -17.24 | |||||
| FCF Yield % | -6.83 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NMRA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Neumora Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.825 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 23.71 | ||
| 14-Day ATR ($) | 0.936947 | ||
| 20-Day SMA ($) | 12.1205 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 8.82 - 21 | ||
| Shares Outstanding (Mil) | 158.89 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Neumora Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Neumora Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Neumora Therapeutics Inc Frequently Asked Questions
What is Neumora Therapeutics Inc(NMRA)'s stock price today?
The current price of NMRA is $9.15. The 52 week high of NMRA is $21.00 and 52 week low is $8.82.
When is next earnings date of Neumora Therapeutics Inc(NMRA)?
The next earnings date of Neumora Therapeutics Inc(NMRA) is 2024-05-31 Est..
Does Neumora Therapeutics Inc(NMRA) pay dividends? If so, how much?
Neumora Therapeutics Inc(NMRA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers